Mizuho healthcare equity strategist Jared Holz discusses Eli Lilly's investment in US manufacturing of GLP-1 weight-loss drugs on Market Domination. The investment aims to enhance production capacity and tackle tariff issues, potentially lowering drug prices.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay